Author of

• 32243

  +

  EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32267

    +

    EP1.16-23 - The Efficacy of S-1 in the Third or More Than Line Treatment of Advanced Non-Small Cell Lung Cancer Patients (ID 1127)

    08:00 - 18:00  |  Author(s): Weihua Wang
    • Abstract

    Background
    

    S-1 as the third generation of fluorouracil derivate with well safety and low toxicity, presented some efficacy in lung cancer treatment. The aim of this study was to evaluate the efficacy of S-1 treatment in advanced non-small cell lung cancer (NSCLC) in a real world.

    Method
    

    We explored the efficacy of S-1 in advanced NSCLC patients with previously treated from 2015 to 2018 in Jiangshan People′s Hospital, Zhejiang Rongjun Hospital and Zhejiang Cancer Hospital. Platinum or the third-generation chemotherapy drugs could be combinedly used. Clinical response was assigned every cycle according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Survival analysis and univariate survival analysis were performed by the Kaplan-Meier method.

    Result
    

    158 patients were included in the research. These patients received S-1 treatment were as a third-line or more-line therapy, including 63 patients S-1 monotherapy, the other 95 patients combined regimens. All 158 NSCLC patients had therapeutic evaluation. Six patients were partial response (PR), and 51 patients were stable disease (SD), then an overall response rate (ORR) was 3.80% and a disease control rate (DCR) was 36.08%. Median progression-free survival (mPFS) was 1.94 months (95%CI 0.56-10.98), no difference between monotherapy and combined group (DCR 30.16% vs 40.00%, P>0.05), the liver metastasis showed poorer PFS (1.29 months vs 1.92 months , P<0.05).

    Conclusion
    

    S-1 presented some activity in advanced NSCLC treated with more than third lines of treatment. The addition of other drugs cannot improve efficacy. S-1 monotherapy can be used as a choice for heavily-treated patients.